British Thoracic Society guidelines for the management of community acquired pneumonia in adults: Update 2009

Thorax

Volumn 64, Issue SUPPL. 3, 2009, Pages

  Lim, Wei Shen ^a   Baudouin Sr , Simon ^b   George, Robert ^c   Hill, Adam ^d   Jamieson, Conor ^e   Le Jeune, Ivan ^a   Macfarlane, John ^f   Read, Robert ^g   Roberts, Helen ^a   Levy, Mark ^h   Wani, Mushtaq ⁱ   Woodhead, Mark ^j  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

ⁱ ABERTAWE BRO MORGANNWG UNIVERSITY HEALTH BOARD   (United Kingdom)

^j MANCHESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL VACCINE; BETA LACTAM; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; PANTON VALENTINE LEUKOCIDIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID;

ADULT; AGING; ALCOHOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ASPIRATION PNEUMONIA; BACTERIUM EXAMINATION; BACTERIUM IDENTIFICATION; BLOOD CULTURE; CHLAMYDOPHILA; CHLAMYDOPHILA PNEUMONIAE; CHLAMYDOPHILA PSITTACI; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY CARE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COXIELLA BURNETII; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG INDICATION; DRUG TREATMENT FAILURE; EMPYEMA; GEOGRAPHIC DISTRIBUTION; GRAM STAINING; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION COMPLICATION; INFECTION PREVENTION; INFLUENZA VIRUS; INTENSIVE CARE; LEGIONNAIRE DISEASE; MEDICAL AUDIT; MORTALITY; MYCOPLASMA PNEUMONIAE; NATIONAL HEALTH ORGANIZATION; NURSING HOME PATIENT; PATIENT EDUCATION; PATIENT MONITORING; PATIENT TRANSPORT; PLEURA EFFUSION; PNEUMOCOCCAL URINE ANTIGEN TEST; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SERODIAGNOSIS; SMOKING CESSATION; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEROID THERAPY; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT DURATION; URINALYSIS; VACCINATION; VIRUS PNEUMONIA;

EID: 77952811646     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.121434     Document Type: Review

References (502)

1. Macfarlane JT, Boswell T, Douglas G, et al. BTS guidelines on the management of community acquired pneumonia in adults. Thorax 2001;56(Suppl 4):1-64.
2. British Thoracic Society Pneumonia Guidelines Committee. BTS guidelines for the management of community acquired pneumonia in adults - 2004 update. 2004. http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/ Pneumonia/ Guidelines/MACAPrevisedApr04.pdf (accessed 15 Dec 2008).
3. Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Semin Respir Infect 1999;14:151-62. (Pubitemid 29269992)
4. Macfarlane J. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect 1994;9:153-65. (Pubitemid 24310383)
5. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99.
6. British Thoracic Society. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987;62:195-220.
7. National Institute for Health and Clinical Excellence (NICE). National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;51(Suppl 1):1-232.
8. British Thoracic Society Standards of Care Committee. Guidelines for the management of community acquired pneumonia in childhood. Thorax 2002;57(Suppl 1).
9. Department of Health and Health Protection Agency. Clostridium difficile infection. How to deal with the problem. Best Practice Guideline. 2008.
10. Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S19-31.
11. Tacconelli E, De Angelis G, Cataldo MA, et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008;61:26-38.
12. Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008;14:727-33.
13. Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006;10(Suppl 2):S1.
14. Royal College of Physicians. Acute medical care. The right person, in the right setting - first time. Report of the Acute Medicine Task Force. London: Royal College of Physicians, 2007.
15. Department of Health. The NHS Plan: a plan for investment, a plan for reform. London: Department of Health, 2000.
16. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
17. Eccles M, Clapp Z, Grimshaw J, et al. North of England evidence based guidelines development project: methods of guideline development. BMJ 1996;312:760-2. (Pubitemid 26091242)
18. Sackett DL. Bias in analytic research. J Chronic Dis 1979;32:51-63.
19. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1994;271:389-91.
20. Scottish Intercollegiate Guidelines Network. Clinical guidelines: criteria for appraisal. Edinburgh: Royal College of Physicians of Edinburgh, 1995.
21. Eddy DM. A manual for assessing health practices and designing practice policies. Philadelphia: American College of Physicians, 1992.
22. Guyatt GH, Sackett DL, Sinclair JC, et al. Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 1995;274:1800-4.
23. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;1:671-4. (Pubitemid 17038913)
24. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88. (Pubitemid 23191065)
25. Foy HM, Cooney MK, Allan I, et al. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979;241:253-8.
26. Macfarlane JT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993;341:511-4. (Pubitemid 23066084)
27. Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Infect 1990;5:260-8.
28. Lave JR, Fine MJ, Sankey SS, et al. Hospitalized pneumonia. Outcomes, treatment patterns, and costs in urban and rural areas. J Gen Intern Med 1996;11:415-21. (Pubitemid 26286783)
29. Marrie TJ, Carriere KC, Jin Y, et al. Factors associated with death among adults <55 years of age hospitalized for community-acquired pneumonia. Clin Infect Dis 2003;36:413-21. (Pubitemid 36241306)
30. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997;10:1530-4. (Pubitemid 27311067)
31. Foy HM, Cooney MK, McMahan R, et al. Viral and mycoplasmal pneumonia in a prepaid medical care group during an eight-year period. Am J Epidemiol 1973;97:93-102.
32. Minogue MF, Coley CM, Fine MJ, et al. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med 1998;31:376-80. (Pubitemid 28135363)
33. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8.
34. Woodhead MA, Macfarlane JT, Rodgers FG, et al. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985;10:204-10. (Pubitemid 15031743)
35. White RJ, Blainey AD, Harrison KJ, et al. Causes of pneumonia presenting to a district general hospital. Thorax 1981;36:566-70. (Pubitemid 11054540)
36. Macfarlane JT, Finch RG, Ward MJ, et al. Hospital study of adult community-acquired pneumonia. Lancet 1982;2:255-8. (Pubitemid 12081777)
37. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001;56:296-301. (Pubitemid 32269810)
38. Karalus NC, Cursons RT, Leng RA, et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991;46:413-8.
39. Lim I, Shaw DR, Stanley DP, et al. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust 1989;151:87-91. (Pubitemid 19187078)
40. Mortensen EM, Kapoor WN, Chang C-CH, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003;37:1617-24. (Pubitemid 37549947)
41. Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc 2007;55:518-25. (Pubitemid 46496572)
42. British Thoracic Society Research Committee and Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992;86:7-13.
43. Alkhayer M, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. Respir Med 1990;84:13-6. (Pubitemid 20116235)
44. Moine P, Vercken JB, Chevret S, et al. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994;105:1487-95.
45. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37. (Pubitemid 28421502)
46. Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med 1998;104:17-27. (Pubitemid 28078374)
47. Howard LSGE, Sillis M, Pasteur MC, et al. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect 2005;50:107-13.
48. Lagerstrom F, Bader M, Foldevi M, et al. Microbiological etiology in clinically diagnosed community-acquired pneumonia in primary care in Orebro, Sweden. Clin Microbiol Infect 2003;9:645-52. (Pubitemid 36987037)
49. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160:397-405. (Pubitemid 29380648)
50. de Roux A, Ewig S, Garcia E, et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006;27:795-800. (Pubitemid 44914205)
51. Gutierrez F, Masia M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005;11:788-800.
52. Fernandez Alvarez R, Suarez Toste I, Rubinos Cuadrado G, et al. Community-acquired pneumonia: aetiologic changes in a limited geographic area. An 11-year prospective study. Eur J Clin Microbiol Infect Dis 2007;26:495-9. (Pubitemid 47025041)
53. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-93. (Pubitemid 46741761)
54. Ngeow Y-F, Suwanjutha S, Chantarojanasriri T, et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. Int J Infect Dis 2005;9:144-53. (Pubitemid 40523759)
55. Diaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007;131:779-87. (Pubitemid 46446870)
56. Matute AJ, Brouwer WP, Hak E, et al. Aetiology and resistance patterns of community-acquired pneumonia in Leon, Nicaragua. Int J Antimicrob Agents 2006;28:423-7. (Pubitemid 44636191)
57. Nagalingam NA, Adesiyun AA, Swanston WH, et al. Seroprevalence of Legionella pneumophila in pneumonia patients in four major hospitals in Trinidad and Tobago. West Indian Med J 2005;54:375-8.
58. Chedid MBF, Ilha DdO, Chedid MF, et al. Community-acquired pneumonia by Legionella pneumophila serogroups 1-6 in Brazil. Respir Med 2005;99:966-75. (Pubitemid 40796539)
59. Marrie TJ, Peeling RW, Reid T, et al. Chlamydia species as a cause of community-acquired pneumonia in Canada. Eur Respir J 2003;21:779-84. (Pubitemid 36592284)
60. Valdivia L, Nix D, Wright M, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia [correction appears in Emerg Infect Dis 2006;12:1307]. Emerg Infect Dis 2006;12:958-62.
61. Wattanathum A, Chaoprasong C, Nunthapisud P, et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 2003;123:1512-9. (Pubitemid 36549770)
62. Bansal S, Kashyap S, Pal LS, et al. Clinical and bacteriological profile of community acquired pneumonia in Shimla, Himachal Pradesh. Indian J Chest Dis Allied Sci 2004;46:17-22.
63. Reechaipichitkul W, Lulitanond V, Sawanyawisuth K, et al. Etiologies and treatment outcomes for out-patients with community-acquired pneumonia (CAP) at Srinagarind Hospital, Khon Kaen, Thailand. Southeast Asian J Trop Med Publ Health 2005;36:1261-7. (Pubitemid 43058848)
64. Yen M-Y, Hu B-S, Chen Y-S, et al. A prospective etiologic study of community-acquired pneumonia in Taiwan. J Formosan Med Assoc 2005;104:724-30. (Pubitemid 44524967)
65. Huang HH, Zhang YY, Xiu QY, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis 2006;25:369-74. (Pubitemid 43885680)
66. Saito A, Kohno S, Matsushima T, et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother 2006;12:63-9.
67. Lauderdale T-L, Chang F-Y, Ben R-J, et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005;99:1079-86. (Pubitemid 41102644)
68. Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004;24:779-85. (Pubitemid 39504431)
69. Venkatesan P, Gladman J, Macfarlane JT, et al. A hospital study of community acquired pneumonia in the elderly. Thorax 1990;45:254-8. (Pubitemid 20143758)
70. Ausina V, Coll P, Sambeat M, et al. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis 1988;7:342-7.
71. Logroscino CD, Penza O, Locicero S, et al. Community-acquired pneumonia in adults: a multicentric observational AIPO study. Monaldi Arch Chest Dis 1999;54:11-7. (Pubitemid 29154859)
72. Leroy O, Vandenbussche C, Coffinier C, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med 1997;156:1922-9. (Pubitemid 28011803)
73. Fernandez-Sabe N, Carratala J, Roson B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine 2003;82:159-69. (Pubitemid 36578705)
74. Ostergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest 1993;104:1400-7.
75. Torres A, Dorca J, Zalacaín R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996;154:1456-61. (Pubitemid 26391197)
76. Marrie TJ. Bacteraemic pneumococcal pneumonia: a continuously evolving disease. J Infect 1992;24:247-55.
77. Marrie TJ, Durant H, Kwan C. Nursing home-acquired pneumonia. A case-control study. J Am Geriatr Soc 1986;34:697-702. (Pubitemid 16028161)
78. Garb JL, Brown RB, Garb JR, et al. Differences in etiology of pneumonias in nursing home and community patients. JAMA 1978;240:2169-72. (Pubitemid 9078560)
79. Drinka PJ, Gauerke C, Voeks S, et al. Pneumonia in a nursing home. J Gen Intern Med 1994;9:650-2. (Pubitemid 24370215)
80. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001;18:362-8. (Pubitemid 32776414)
81. Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1393-9. (Pubitemid 47052438)
82. Sopena N, Sabrià-Leal M, Pedro-Botet ML, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 1998;113:1195-200. (Pubitemid 28223804)
83. de Roux A, Cavalcanti M, Marcos MA, et al. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. Chest 2006;129:1219-25.
84. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997;337:682-7.
85. Mier L, Dreyfuss D, Darchy B, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993;19:279-84. (Pubitemid 23266000)
86. de Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004;125:1343-51. (Pubitemid 38501348)
87. Kim PE, Musher DM, Glezen WP, et al. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis 1996;22:100-6. (Pubitemid 26022019)
88. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991;99:147-51.
89. Naik FC, Ricketts KD, Harrison TG, et al. Legionnaires' disease in England and Wales (1995-2005). Health Protection Report 2008. 2008.
90. Newton LH, Joseph CA, Hutchinson EJ, et al. Legionnaires' disease surveillance: England and Wales, 1995. Commun Dis Rep CDR Rev 1996;6:R151-5.
91. Joseph CA, Harrison TG, Ilijic-Car D, et al. Legionnaires' disease in residents of England and Wales: 1998. Commun Dis Public Health 1999;2:280-4.
92. Joseph CA, Harrison TG, Ilijic-Car D, et al. Legionnaires' disease in residents of England and Wales: 1996. Commun Dis Rep CDR Rev 1997;7:R153-9.
93. Saikku P, Wang SP, Kleemola M, et al. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985;151:832-9. (Pubitemid 15094599)
94. Kleemola M, Saikku P, Visakorpi R, et al. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis 1988;157:230-6. (Pubitemid 18061234)
95. Troy CJ, Peeling RW, Ellis AG, et al. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997;277:1214-8. (Pubitemid 27172744)
96. Wellinghausen N, Straube E, Freidank H, et al. Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. Int J Med Microbiol 2006;296:485-91. (Pubitemid 44572968)
97. Steinhoff D, Lode H, Ruckdeschel G, et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996;22:958-64. (Pubitemid 26260595)
98. Lieberman D, Ben-Yaakov M, Lazarovich Z, et al. Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. Infection 1996;24:109-14. (Pubitemid 26137087)
99. Kauppinen MT, Saikku P, Kujala P, et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996;51:185-9. (Pubitemid 26060656)
100. Wreghitt T. Chlamydial infection of the respiratory tract. Commun Dis Rep CDR Rev 1993;3:R119-24.
101. Pebody RG, Wall PG, Ryan MJ, et al. Epidemiological features of Coxiella burnetii infection in England and Wales: 1984 to 1994. Commun Dis Rep CDR Rev 1996;6:R128-32.
102. McNabb WR, Shanson DC, Williams TD, et al. Adult community-acquired pneumonia in central London. J R Soc Med 1984;77:550-5. (Pubitemid 15206222)
103. Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997;52:17-21. (Pubitemid 27047219)
104. Rotas M, McCalla S, Liu C, et al. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. Obstet Gynecol 2007;109:533-6. (Pubitemid 46151037)
105. Asnis D, Haralambou G, Tawiah P, et al. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. Obstet Gynecol 2007;110:188. (Pubitemid 47015722)
106. Garnier F, Tristan A, Francois B, et al. Pneumonia and new methicillin-resistant Staphylococcus aureus clone. Emerg Infect Dis 2006;12:498-500.
107. Nimmo GR, Playford EG. Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia. Med J Aust 2003;178:245. (Pubitemid 36329223)
108. Peleg AY, Munckhof WJ. Fatal necrotising pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (MRSA). Med J Aust 2004;181:228-9. (Pubitemid 39172946)
109. Risson DC, O'Connor ED, Guard RW, et al. A fatal case of necrotising pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. Med J Aust 2007;186:479-80. (Pubitemid 46806827)
110. Vayalumkal JV, Whittingham H, Vanderkooi O, et al. Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM Can J Emerg Med Care 2007;9:300-3. (Pubitemid 47232899)
111. Monaco M, Antonucci R, Palange P, et al. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis 2005;11:1647-8. (Pubitemid 41384367)
112. Torell E, Molin D, Tano E, et al. Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scand J Infect Dis 2005;37:902-4.
113. Soderquist B, Berglund C, Stralin K. Community-acquired pneumonia and bacteremia caused by an unusual methicillin-resistant Staphylococcus aureus (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. Eur J Clin Microbiol Infect Dis 2006;25:604-6. (Pubitemid 44379696)
114. Magira EE, Zervakis D, Routsi C, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: a lethal cause of pneumonia in an adult immunocompetent patient. Scand J Infect Dis 2007;39:466-9. (Pubitemid 46705761)
115. Klein JL, Petrovic Z, Treacher D, et al. Severe community-acquired pneumonia caused by Panton-Valentine leukocidin-positive Staphylococcus aureus: first reported case in the United Kingdom. Intensive Care Med 2003;29:1399. (Pubitemid 37041177)
116. Honarpour N, Mao JT. A Case of fatal community-acquired necrotizing pneumonia caused by panton-valentine leukocidin positive methicillin-sensitive Staphylococcus aureus. Curr Respir Med Rev 2007;3:49-51. (Pubitemid 46358530)
117. Beilouny B, Ciupea A, Eloy C, et al. Fatal community-acquired pneumonia due to Staphylococcus aureus carrying Panton-Valentine leukocidin genes after a stay in Africa. Intensive Care Med 2008;34:388-9. (Pubitemid 351207634)
118. Baldwin LN, Lowe AD. Panton-Valentine Leukocidin associated with community acquired methicillin resistant Staphylococcus aureus: a case report and review of interim guidelines. Anaesthesia 2008;63:764-6. (Pubitemid 351814233)
119. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:100-7. (Pubitemid 40053465)
120. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12:894-9.
121. Chua AP, Lee KH. Fatal bacteraemic pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus. Singapore Med J 2006;47:546-8. (Pubitemid 43900504)
122. Anon. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR - Morbidity & Mortality Weekly Report 2007;56:325-9.
123. Hyvernat H, Pulcini C, Carles D, et al. Fatal Staphylococcus aureus haemorrhagic pneumonia producing Panton-Valentine leucocidin. Scand J Infect Dis 2007;39:183-5. (Pubitemid 46277325)
124. Balis E, Diacaki C, Tselioti P, et al. Community-acquired pneumonia and bacteremia due to methicillin-resistant Staphylococcus aureus carrying Panton-Valentine-leukocidin gene in Greece: two case reports and literature review. J Chemother 2007;19:703-8. (Pubitemid 351212021)
125. Hutchinson EJ, Joseph CA, Zambon M, et al. Influenza surveillance in England and Wales: October 1995 to June 1996. Commun Dis Rep CDR Rev 1996;6:R163-9.
126. Connolly AM, Salmon RL, Lervy B, et al. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. BMJ 1993;306:1452-4.
127. Farr BM, Kaiser DL, Harrison BD, et al. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989;44:1031-5. (Pubitemid 20020727)
128. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990;69:307-16.
129. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996;154:1450-5. (Pubitemid 26391196)
130. Bohte R, Hermans J, van den Broek PJ. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:201-5. (Pubitemid 26125756)
131. Helms CM, Wintermeyer LA, Zeitler RR, et al. An outbreak of community-acquired Legionnaires' disease pneumonia. Am J Public Health 1984;74:835-6. (Pubitemid 14090522)
132. Granados A, Podzamczer D, Gudiol F, et al. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: similarities and differences on presentation. Eur Respir J 1989;2:130-4. (Pubitemid 19068709)
133. Fernandez-Sabe N, Roson B, Carratala J, et al. Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. Clin Infect Dis 2003;37:483-9. (Pubitemid 37011770)
134. Lieberman D, Porath A, Schlaeffer F, et al. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest 1996;109:1243-9.
135. Falcó V, Fernández de Sevilla T, Alegre J, et al. Legionella pneumophila. A cause of severe community-acquired pneumonia. Chest 1991;100:1007-11.
136. Helms CM, Viner JP, Sturm RH, et al. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. Ann Intern Med 1979;90:543-7. (Pubitemid 9180964)
137. Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med 1993;153:488-94. (Pubitemid 23064992)
138. Puljiz I, Kuzman I, Dakovic-Rode O, et al. Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles. Epidemiol Infect 2006;134:548-55.
139. File TM Jr, Plouffe JF Jr, Breiman RF, et al. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin Infect Dis 1999;29:426-8. (Pubitemid 29380211)
140. Lieberman D, Boldur I, Manor E, et al. Q-fever pneumonia in the Negev region of Israel: a review of 20 patients hospitalised over a period of one year. J Infect 1995;30:135-40.
141. Goyette M, Bouchard J, Poirier A, et al. Importance of Q fever in community acquired pneumonia. Can J Infect Dis 1996;7:370-3. (Pubitemid 27032136)
142. Sobradillo V, Ansola P, Baranda F, et al. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. Eur Respir J 1989;2:263-6. (Pubitemid 19107109)
143. Caron F, Meurice JC, Ingrand P, et al. Acute Q fever pneumonia: a review of 80 hospitalized patients. Chest 1998;114:808-13. (Pubitemid 28433745)
144. Feldman C, Kallenbach JM, Levy H, et al. Comparison of bacteraemic community-acquired lobar pneumonia due to Streptococcus pneumoniae and Klebsiella pneumoniae in an intensive care unit. Respiration 1991;58:265-70.
145. Rudin ML, Michael JR, Huxley EJ. Community-acquired acinetobacter pneumonia. Am J Med 1979;67:39-43. (Pubitemid 9230703)
146. Henderson A, Wall D. Streptococcus milleri liver abscess presenting as fulminant pneumonia. Aust N Z J Surg 1993;63:237-40. (Pubitemid 23131824)
147. Goolam MA, Feldman C, Smith C, et al. Does primary Streptococcus viridans pneumonia exist? S Afr Med J 1992;82:432-4.
148. Marrie TJ. Pneumonia in the elderly. Curr Opin Pulm Med 1996;2:192-7. (Pubitemid 126442490)
149. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997;157:1453-9. (Pubitemid 27300393)
150. Riquelme R, Torres A, el-Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med 1997;156:1908-14. (Pubitemid 28011801)
151. Marrie TJ, Haldane EV, Faulkner RS, et al. Community-acquired pneumonia requiring hospitalization. Is it different in the elderly? J Am Geriatr Soc 1985;33:671-80.
152. Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994;150:251-3.
153. Marrie TJ, Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. J Am Geriatr Soc 1997;45:50-5. (Pubitemid 27024605)
154. Reza Shariatzadeh M, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. J Am Geriatr Soc 2006;54:296-302.
155. Bartlett JG, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. Am J Med 1974;56:202-7.
156. Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999;115:178-83. (Pubitemid 29047072)
157. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003;167:1650-4. (Pubitemid 36760678)
158. Ott SR, Allewelt M, Lorenz J, et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008;36:23-30.
159. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440-5. (Pubitemid 27475974)
160. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-18. (Pubitemid 36222498)
161. Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting physical signs in examination of the chest. Lancet 1988;1:873-5. (Pubitemid 18092412)
162. Melbye H, Straume B, Aasebø U, et al. The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests. Scand J Prim Health Care 1988;6:111-7.
163. Diehr P, Wood RW, Bushyhead J, et al. Prediction of pneumonia in outpatients with acute cough - a statistical approach. J Chronic Dis 1984;37:215-25. (Pubitemid 14194686)
164. O'Brien WT Sr, Rohweder DA, Lattin GE Jr, et al. Clinical indicators of radiographic findings in patients with suspected community-acquired pneumonia: who needs a chest x-ray? [correction appears in J Am Coll Radiol 2006;3:A4]. J Am Coll Radiol 2006;3:703-6. (Pubitemid 44280050)
165. Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001;56:109-14. (Pubitemid 32142674)
166. Macfarlane JT, Miller AC, Roderick Smith WH, et al. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax 1984;39:28-33. (Pubitemid 14154207)
167. Kauppinen MT, Lähde S, Syrjälä H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch Intern Med 1996;156:1851-6.
168. Gikas A, Kofteridis D, Bouros D, et al. Q fever pneumonia: appearance on chest radiographs. Radiology 1999;210:339-43. (Pubitemid 29055298)
169. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996;101:508-15. (Pubitemid 126335971)
170. Macfarlane J, Rose D. Radiographic features of staphylococcal pneumonia in adults and children. Thorax 1996;51:539-40. (Pubitemid 26160479)
171. Korvick JA, Hackett AK, Yu VL, et al. Klebsiella pneumonia in the modern era: clinicoradiographic correlations. South Med J 1991;84:200-4.
172. Syrjälä H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998;27:358-63. (Pubitemid 28365760)
173. Reittner P, Müller NL, Heyneman L, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol 2000;174:37-41. (Pubitemid 30030203)
174. Beall DP, Scott WW Jr, Kuhlman JE, et al. Utilization of computed tomography in patients hospitalized with community-acquired pneumonia. Md Med J 1998;47:182-7.
175. Tanaka N, Matsumoto T, Kuramitsu T, et al. High resolution CT findings in community-acquired pneumonia. J Comput Assist Tomogr 1996;20:600-8. (Pubitemid 26244417)
176. Mittl RL Jr, Schwab RJ, Duchin JS, et al. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994;149(3 Pt 1):630-5. (Pubitemid 24082218)
177. El Solh AA, Aquilina AT, Gunen H, et al. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004;52:224-9. (Pubitemid 38233484)
178. Bruns AHW, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007;45:983-91. (Pubitemid 47580346)
179. Jay SJ, Johanson WG Jr, Pierce AK. The radiographic resolution of Streptococcus pneumoniae pneumonia. N Engl J Med 1975;293:798-801.
180. Granet KM, Wallach SL, Horvath K, et al. Chest radiographs in patients with community-acquired pneumonia. N J Med 1996;93:37-41.
181. Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up. Scand J Infect Dis 1993;25:93-100. (Pubitemid 23099590)
182. Gibson SP, Weir DC, Burge PS. A prospective audit of the value of fibre optic bronchoscopy in adults admitted with community acquired pneumonia. Respir Med 1993;87:105-9. (Pubitemid 23099766)
183. British Thoracic Society. BTS guideline for emergency oxygen use in adult patients. Thorax 2008;63(Suppl 6):vi1-68.
184. Holmberg H, Bodin L, Jönsson I, et al. Rapid aetiological diagnosis of pneumonia based on routine laboratory features. Scand J Infect Dis 1990;22:537-45. (Pubitemid 20354249)
185. Castro-Guardiola A, Armengou-Arxe A, Viejo-Rodriguez A, et al. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur J Intern Med 2000;11:334-9.
186. Smith RP, Lipworth BJ, Cree IA, et al. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995;108:1288-91.
187. Hansson LO, Hedlund JU, Ortqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest 1997;57:111-8. (Pubitemid 27242809)
188. Flanders SA, Stein J, Shochat G, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004;116:529-35. (Pubitemid 38452644)
189. Ortqvist A, Hedlund J, Wretlind B, et al. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995;27:457-62.
190. Garcia Vazquez E, Martinez JA, Mensa J, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003;21:702-5. (Pubitemid 36432528)
191. Sanyal S, Smith PR, Saha AC, et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-8. (Pubitemid 29326111)
192. Menéndez R, Córdoba J, de La Cuadra P, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999;159:1868-73. (Pubitemid 29275056)
193. Ewig S, Bauer T, Hasper E, et al. Value of routine microbial investigation in community-acquired pneumonia. Can J Infect Dis 1996;63:169.
194. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, et al. The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991;85:313-7.
195. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241-9. (Pubitemid 40768492)
196. Hohenthal U, Vainionpaa R, Meurman O, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis 2008;40:131-8.
197. Templeton KE, Scheltinga SA, van den Eeden WCJFM, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005;41:345-51. (Pubitemid 41022112)
198. Theerthakarai R, El-Halees W, Ismail M, et al. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001;119:181-4. (Pubitemid 32150565)
199. Ewig S, Schlochtermeier M, Goke N, et al. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002;121:1486-92. (Pubitemid 34499660)
200. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82. (Pubitemid 32621991)
201. Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003;123:1142-50. (Pubitemid 36444372)
202. Woodhead M, Macfarlane J. Local antibiotic guidelines for adult community-acquired pneumonia (CAP): a survey of UK hospital practice in 1999. J Antimicrob Chemother 2000;46:141-3. (Pubitemid 30466212)
203. Chambers DC, Waterer GW. Are blood cultures necessary in community-acquired pneumonia? Clin Pulmon Med 2005;12:146-52.
204. Benenson RS, Kepner AM, Pyle DN 2nd, et al. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007;33:1-8. (Pubitemid 47042314)
205. Ramanujam P, Rathlev NK. Blood cultures do not change management in hospitalized patients with community-acquired pneumonia. Acad Emerg Med 2006;13:740-5. (Pubitemid 43928651)
206. Corbo J, Friedman B, Bijur P, et al. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004;21:446-8. (Pubitemid 38967457)
207. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82. (Pubitemid 32289567)
208. Taylor EL, Marrie TJ, Fine MJ, et al. Observations from a multicentre study on the use of the sputum specimen in patients hospitalized with community-acquired pneumonia. Can J Infect Dis 1999;10:39-46. (Pubitemid 29173897)
209. Reed WW, Byrd GS, Gates RH Jr, et al. Sputum gram's stain in community-acquired pneumococcal pneumonia. A meta-analysis. West J Med 1996;165:197-204. (Pubitemid 26391580)
210. Rein MF, Gwaltney JM Jr, O'Brien WM, et al. Accuracy of Gram's stain in identifying pneumococci in sputum. JAMA 1978;239:2671-3. (Pubitemid 8383566)
211. Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004;164:1807-11. (Pubitemid 39215654)
212. Miyashita N, Shimizu H, Ouchi K, et al. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 2008;14:CR171-6.
213. Fine MJ, Orloff JJ, Rihs JD, et al. Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med 1991;6:189-98.
214. Croce MA, Fabian TC, Waddle-Smith L, et al. Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: a prospective study. Ann Surg 1998;227:743-55. (Pubitemid 28530924)
215. Roberts ME, Macfarlane JT, George RC, et al. Microbiology investigations in community acquired pneumonia - most laboratories in England and Wales do not offer all those recommended in the British Thoracic Society guideline. J Infect 2008;56:291-4.
216. Venkatesan P, Macfarlane JT. Role of pneumococcal antigen in the diagnosis of pneumococcal pneumonia. Thorax 1992;47:329-31.
217. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001;39:3495-8. (Pubitemid 32954491)
218. Andreo F, Dominguez J, Ruiz J, et al. Impact of rapid urine antigen tests to determine the etiology of community-acquired pneumonia in adults. Respiratory Medicine 2006;100:884-91.
219. Briones ML, Blanquer J, Ferrando D, et al. Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. Clin Vaccine Immunol 2006;13:1092-7. (Pubitemid 44622535)
220. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003;36:286-92. (Pubitemid 36169663)
221. Kobashi Y, Yoshida K, Miyashita N, et al. Evaluating the use of a Streptococcus pneumoniae urinary antigen detection kit for the management of community-acquired pneumonia in Japan. Respiration 2007;74:387-93. (Pubitemid 47093150)
222. Lasocki S, Scanvic A, Le Turdu F, et al. Evaluation of the Binax NOW Streptococcus pneumoniae urinary antigen assay in intensive care patients hospitalized for pneumonia. Intensive Care Med 2006;32:1766-72. (Pubitemid 44607364)
223. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003;41:2810-3. (Pubitemid 36842263)
224. Porcel JM, Ruiz-Gonzalez A, Falguera M, et al. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. Chest 2007;131:1442-7. (Pubitemid 46762350)
225. Sheppard CL, Harrison TG, Kearns AM, et al. Diagnosis of invasive pneumococcal infection by PCR amplification of Streptococcus pneumoniae genomic fragments in blood: a multi-centre comparative study. Commun Dis Public Health 2003;6:221-7.
226. Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. J Clin Microbiol 2003;41:63-6. (Pubitemid 36098554)
227. Birtles RJ, Harrison TG, Samuel D, et al. Evaluation of urinary antigen ELISA for diagnosing Legionella pneumophila serogroup 1 infection. J Clin Pathol 1990;43:685-90. (Pubitemid 20228933)
228. Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002;8:1448-54. (Pubitemid 36008783)
229. Helbig JH, Uldum So A, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial Legionnaires' disease. J Clin Microbiol 2003;41:838-40. (Pubitemid 36184210)
230. Boswell TC, Marshall LE, Kudesia G. False-positive legionella titres in routine clinical serology testing detected by absorption with campylobacter: implications for the serological diagnosis of legionnaires' disease. J Infect 1996;32:23-6. (Pubitemid 26120056)
231. Medical Devices Agency. Mycoplasma pneumoniae antibody assays. Medical Devices Agency Evaluation Report MDA/98/62, 1998.
232. Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005;43:2277-85.
233. Daxboeck F, Khanakah G, Bauer C, et al. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR [correction appears in Int J Med Microbiol 2006;296:55]. Int J Med Microbiol 2005;295:279-85.
234. Sillis M, White P, Caul EO, et al. The differentiation of Chlamydia species by antigen detection in sputum specimens from patients with community-acquired acute respiratory infections. J Infect 1992;25(Suppl 1):77-86.
235. Garnett P, Brogan O, Lafong C, et al. Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence. J Clin Pathol 1998;51:309-11. (Pubitemid 28281003)
236. Boman J, Allard A, Persson K, et al. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. J Infect Dis 1997;175:1523-6. (Pubitemid 27225063)
237. Sillis M, Wreghitt TG, Paul ID, et al. Chlamydial respiratory infections. Don't get bogged down by differentiating species. BMJ 1993;307:62-3.
238. Kutlin A, Tsumura N, Emre U, et al. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Clin Diagn Lab Immunol 1997;4:213-6. (Pubitemid 27130236)
239. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8. (Pubitemid 28489008)
240. Meyer RJ, Town GI, Harrè E, et al. An audit of the assessment and management of adults admitted to Christchurch Hospital with community acquired pneumonia. NZ Med J 1997;110:349-52. (Pubitemid 27443684)
241. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-6. (Pubitemid 26360177)
242. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36.
243. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
244. Fine MJ, Singer DE, Hanusa BH, et al. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993;94:153-9. (Pubitemid 23046440)
245. Hedlund J, Kalin M, Ortqvist A. Recurrence of pneumonia in middle-aged and elderly adults after hospital-treated pneumonia: aetiology and predisposing conditions. Scand J Infect Dis 1997;29:387-92.
246. Conte HA, Chen YT, Mehal W, et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 1999;106:20-8. (Pubitemid 29077138)
247. Kothe H, Bauer T, Marre R, et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008;32:139-46.
248. Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med 1995;10:359-68.
249. Pachon J, Prados MD, Capote F, et al. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990;142:369-73.
250. Leroy O, Santré C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21:24-31.
251. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. (Pubitemid 27044625)
252. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105-13.
253. Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001;20:14-9. (Pubitemid 32200356)
254. van Eeden SF, Coetzee AR, Joubert JR. Community-acquired pneumonia - factors influencing intensive care admission. S Afr Med J 1988;73:77-81. (Pubitemid 18073004)
255. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. (Pubitemid 36560938)
256. Gómez J, Baños V, Ruiz Gómez J, et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:556-60. (Pubitemid 26273211)
257. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-25. (Pubitemid 351317927)
258. Leroy O, Georges H, Beuscart C, et al. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med 1996;22:1307-14. (Pubitemid 27007763)
259. Hasley PB, Albaum MN, Li YH, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med 1996;156:2206-12.
260. Feldman C, Kallenbach JM, Levy H, et al. Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a "severity of illness" core. Intensive Care Med 1989;15:302-7. (Pubitemid 19213224)
261. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;28:68-73. (Pubitemid 30189610)
262. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients' outcome research team pneumonia severity index. Chest 2005;128:2223-9. (Pubitemid 41507563)
263. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006;32:469-72. (Pubitemid 43289660)
264. Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349-55.
265. Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005;33:257-63. (Pubitemid 41152186)
266. Tejera A, Santolaria F, Diez ML, et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 2007;38:117-23. (Pubitemid 47248295)
267. Aalto H, Takala A, Kautiainen H, et al. Monocyte CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection. Scand J Infect Dis 2007;39:596-603. (Pubitemid 47009171)
268. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 2006;10:R96.
269. Coelho L, Povoa P, Almeida E, et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11(28).
270. Kruger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and provasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 2007;33:2069-78. (Pubitemid 350164580)
271. Prat C, Lacoma A, Dominguez J, et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007;55:400-7. (Pubitemid 47611511)
272. Brunkhorst FM, Al-Nawas B, Krummenauer F, et al. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002;8:93-100.
273. Shilon Y, Shitrit AB-G, Rudensky B, et al. A rapid quantitative D-dimer assay at admission correlates with the severity of community acquired pneumonia. Blood Coagul Fibrinolysis 2003;14:745-8.
274. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma D-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004;126:1087-92. (Pubitemid 39391236)
275. Tapson VF. Risk factors in community-acquired pneumonia: can they be quantified? Eur Respir Rev 1998;8:291-4.
276. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds [comment]. Eur Respir J 2006;27:9-11. (Pubitemid 43092660)
277. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997;278:32-9. (Pubitemid 27274513)
278. Marras TK, Chan CK. Use of guidelines in treating community-acquired pneumonia. Chest 1998;113:1689-94. (Pubitemid 28307179)
279. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998;158:1350-6. (Pubitemid 28287529)
280. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881-94. (Pubitemid 46205946)
281. Renaud B, Coma E, Labarere J, et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007;44:41-9. (Pubitemid 44968982)
282. Richeldi L, De Guglielmo M, Fabbri LM, et al. Management of CAP using a validated risk score. Thorax 2005;60:172-3. (Pubitemid 40222905)
283. Barlow G, Nathwani D, Williams F, et al. Reducing door-to-antibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and costeffectiveness analysis. Thorax 2007;62:67-74. (Pubitemid 46110371)
284. Tang CM, Macfarlane JT. Early management of younger adults dying of community acquired pneumonia. Respir Med 1993;87:289-94. (Pubitemid 23194336)
285. Gladman J, Barer D, Venkatesan P, et al. Outcome of pneumonia in the elderly: a hospital survey. Clin Rehab 1991;5:201-5.
286. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006;27:151-7. (Pubitemid 43092679)
287. Myint PK, Kamath AV, Vowler SL, et al. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts. Age Ageing 2006;35:286-91.
288. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118:384-92. (Pubitemid 40460997)
289. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007;62:253-9. (Pubitemid 46579808)
290. Spindler C, Ortqvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. Eur Respir J 2006;28:816-23. (Pubitemid 46332004)
291. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006;61:419-24. (Pubitemid 43723326)
292. Shindo Y, Sato S, Maruyama E, et al. Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology 2008;13:731-5. (Pubitemid 351977599)
293. Loh L-C. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity. Med J Malaysia 2006;61:128-30.
294. Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006;174:1249-56. (Pubitemid 44924826)
295. Ananda-Rajah MR, Charles PG, Melvani S, et al. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 2008;40:293-300. (Pubitemid 351447991)
296. Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260:93-101. (Pubitemid 43894075)
297. Schaaf B, Kruse J, Rupp J, et al. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007;30:517-24. (Pubitemid 351182076)
298. Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007;62:348-53. (Pubitemid 46580578)
299. Bont J, Hak E, Hoes AW, et al. A prediction rule for elderly primary-care patients with lower respiratory tract infections. Eur Respir J 2007;29:969-75. (Pubitemid 46711903)
300. Myint PK, Kamath AV, Vowler SL, et al. Simple modification of CURB-65 better identifies patients including the elderly with severe CAP. Thorax 2007;62:1015-6. (Pubitemid 350084507)
301. Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004;59:421-7. (Pubitemid 38624749)
302. Buising KL, Thursky KA, Black JF, et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas 2007;19:418-426. (Pubitemid 47547572)
303. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-84. (Pubitemid 352009359)
304. Leroy O, Devos P, Guery B, et al. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. Chest 1999;116:157-65. (Pubitemid 29340277)
305. Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000;94:422-7. (Pubitemid 30352997)
306. Tydeman DE, Chandler AR, Graveling BM, et al. An investigation into the effects of exercise tolerance training on patients with chronic airways obstruction. Physiotherapy 1984;70:261-4.
307. LaCroix AZ, Lipson S, Miles TP, et al. Prospective study of pneumonia hospitalizations and mortality of U.S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep 1989;104:350-60. (Pubitemid 19207539)
308. Levin KP, Hanusa BH, Rotondi A, et al. Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. J Gen Intern Med 2001;16:590-8. (Pubitemid 32823889)
309. Fulmer JD, Snider GL. American College of Chest Physicians/National Heart, Lung, and Blood Institute National Conference on Oxygen Therapy. Heart Lung 1984;13:550-62.
310. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-55.
311. Scottish Intercollegiate Guideline Network. Prophylaxis of venous thromboembolism. 2002. http://www.sign.ac.uk/guidelines/fulltext/62/index.html.
312. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-9. (Pubitemid 30045469)
313. NHS Lothian. NHS Lothian Antithrombotic Guide. 2006.
314. Mundy LM, Leet TL, Darst K, et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003;124:883-9. (Pubitemid 37123304)
315. Tydeman DE. An investigation into the effectiveness of physiotherapy in the treatment of patients with community acquired pneumonia. Physio Pract 1989;5:75-8.
316. Björkqvist M, Wiberg B, Bodin L, et al. Bottle-blowing in hospital-treated patients with community-acquired pneumonia. Scand J Infect Dis 1997;29:77-82.
317. National Institute for Health and Clinical Excellence (NICE). Acutely ill patients in hospital. Clinical Guideline 50. July 2007.
318. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-52. (Pubitemid 351692355)
319. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002;162:1278-84. (Pubitemid 34595034)
320. Dagan E, Novack V, Porath A. Adverse outcomes in patients with community acquired pneumonia discharged with clinical instability from Internal Medicine Department. Scand J Infect Dis 2006;38:860-6. (Pubitemid 44489514)
321. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
322. Demoule A, Girou E, Richard J-C, et al. Benefits and risks of success or failure of noninvasive ventilation. Intensive Care Med 2006;32:1756-65. (Pubitemid 44607363)
323. Sinuff T, Cook DJ. Health technology assessment in the ICU: noninvasive positive pressure ventilation for acute respiratory failure. J Crit Care 2003;18:59-67. (Pubitemid 36356521)
324. Keenan SP, Sinuff T, Cook DJ, et al. Does noninvasive positive pressure ventilation improve outcome in acute hypoxemic respiratory failure? A systematic review. Crit Care Med 2004;32:2516-23. (Pubitemid 39648237)
325. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999;160:1585-91.
326. Delclaux C, L'Her E, Alberti C, et al. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: a randomized controlled trial. JAMA 2000;284:2352-60.
327. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. (Pubitemid 32204987)
328. Laterre P-F, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005;33:952-61. (Pubitemid 40638163)
329. Marti-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008;(1):CD004388.
330. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-8.
331. Gorman SK, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007;41:1233-7. (Pubitemid 47122561)
332. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
333. Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2007;(2):CD004400.
334. Leroy O, Guilley J, Georges H, et al. Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia. J Crit Care 1999;14:12-9. (Pubitemid 29129403)
335. Caine M, Lim WS, Macfarlane JT, et al. Keeping patients informed about their illness: community acquired pneumonia. Thorax 2000;55(Suppl 3):A71.
336. Impallomeni M, Galletly NP, Wort SJ, et al. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995;311:1345-6.
337. Riley TV. Clostridium difficile: a pathogen of the nineties. Eur J Clin Microbiol Infect Dis 1998;17:137-41.
338. Zadik PM, Moore AP. Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect 1998;39:189-93. (Pubitemid 28362384)
339. MacGowan AP, Feeney R, Brown I, et al. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1997;39:537-41. (Pubitemid 27196954)
340. Settle CD, Wilcox MH, Fawley WN, et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998;12:1217-23. (Pubitemid 28565961)
341. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41(Suppl C):21-7. (Pubitemid 28230296)
342. Ludlum H, Brown N, Sule O, et al. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea. Age Aging 1999;28:578-80. (Pubitemid 29535338)
343. Johnson AP. Antibiotic resistance among clinically important gram-positive bacteria in the UK. J Hosp Infect 1998;40:17-26. (Pubitemid 28438967)
344. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. J Chemother 1999;11(Suppl 1):5-21.
345. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
346. Einarsson S, Kristjansson M, Kristinsson KG, et al. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis 1998;30:253-6. (Pubitemid 28461593)
347. Klugman K, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumoccocal pneumonia. Infect Dis Clin Pract 1998;7:180-4. (Pubitemid 28293388)
348. Pallares R, Viladrich PF, Linares J, et al. Impact of antibiotic resistance on chemotherapy for pneumococcal infections. Microb Drug Resist 1998;4:339-47. (Pubitemid 29180105)
349. Garau J, Aguilar L, Rodriguez-Creixems M, et al. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with beta-lactam monotherapy. J Chemother 1999;11:266-72. (Pubitemid 29382621)
350. Ewig S, Kleinfeld T, Bauer T, et al. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999;14:370-5. (Pubitemid 29461304)
351. Farrell DJ, Felmingham D, Shackcloth J, et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 2008;62(Suppl 2):ii87-95.
352. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.
353. Powell M, Yeo SF, Seymour A, et al. Antimicrobial resistance in Haemophilus influenzae from England and Scotland in 1991. J Antimicrob Chemother 1992;29:547-54.
354. Morrissey I, Maher K, Williams L, et al. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007. J Antimicrob Chemother 2008;62(Suppl 2):ii97-103.
355. Andrews J, Ashby J, Jevons G, et al. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. J Antimicrob Chemother 2000;45:285-93.
356. Nielsen K, Bangsborg JM, Hoiby N. Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin. Diagn Microbiol Infect Dis 2000;36:43-8. (Pubitemid 30085485)
357. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995;8:1999-2007.
358. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999;44:835-8.
359. Hoffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-64. (Pubitemid 32624519)
360. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95. (Pubitemid 32150566)
361. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med 1999:748-63.
362. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43. (Pubitemid 36150313)
363. Anon. Britsh National Formulary. London: BMJ Publishing Group and RPS Publishing, 2008.
364. Anderson G, Esmonde TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991;27(Suppl A):117-24.
365. Chien SM, Pichotta P, Siepman N, et al. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993;103:697-701.
366. Green JA, Butler T, Todd WM. Randomized double-blind trial of the comparative efficacy and safety of cefpodoxime proxetil and cefaclor in the treatment of acute community-acquired pneumonia. Curr Ther Res 1994;55:1003-15. (Pubitemid 24303660)
367. Rizzato G, Allegra L. Efficacy and tolerability of a teicoplanin- ciprofloxacin combination in severe community-acquired pneumonia. Clin Drug Invest 1997;14:337-45.
368. Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995;14:182-7.
369. Chan R, Hemeryck L, O'Regan M, et al. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ 1995;310:1360-2.
370. Plouffe JF, Herbert MT, File TM Jr, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob Agents Chemother 1996;40:1175-9. (Pubitemid 26136030)
371. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72. (Pubitemid 27383238)
372. Van den Brande P, Vondra V, Vogel F, et al. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997;112:406-15. (Pubitemid 27349431)
373. Vetter N, Stamler D, O'Neill S, et al. Clarithromycin vs combined cefuroxime and erythromycin in the treatment of hospitalized community-acquired pneumonia patients: intravenous followed by oral therapy. Clin Drug Invest 1997;14:439-49. (Pubitemid 28025060)
374. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998;17:828-33. (Pubitemid 29219147)
375. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clin Microbiol Infect 1999;5:724-32. (Pubitemid 30047839)
376. Rovira E, Martinez-Moragon E, Belda A, et al. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration 1999;66:413-8. (Pubitemid 29431574)
377. Johnson RH, Levine S, Traub SL. Sequential intravenous/oral ciprofloxacin compared with parenteral ceftrixone in the treatment of hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1996;5:265-72. (Pubitemid 26198371)
378. Bartoloni A, Strohmeyer M, Corti G, et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res 1999;25:243-52. (Pubitemid 30093772)
379. Garau J, Twynholm M, Garcia-Mendez E, et al. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003;52:826-36.
380. Siquier B, Sanchez-Alvarez J, Garcia-Mendez E, et al. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006;57:536-45.
381. Dunbar LM. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance. Am J Med Sci 2003;326:360-8. (Pubitemid 37523569)
382. Baumgartner JD, Glauser MP. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia. Am J Med 1984;77:54-8. (Pubitemid 15209247)
383. Fredlund H, Bodin L, Back E, et al. Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin. Scand J Infect Dis 1987;19:459-66. (Pubitemid 17131876)
384. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990;26(Suppl E):71-7.
385. Poirier R. Comparative study of clarithromycin and roxithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1991;27(Suppl A):109-16.
386. Koulla-Shiro S, Kuaban C, Auckenthaler R, et al. Adult response to initial treatment with ampicillin in community acquired pneumonia in Yaounde, Cameroon. Cent Afr J Med 1993;39:188-92. (Pubitemid 24254517)
387. Gaillat J, Bru JP, Sedallian A. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994;13:639-44. (Pubitemid 24286863)
388. Low DE, Mandell LA. A prospective open-label multi-centre trial on the use of 1 g, once daily ceftriaxone in lower respiratory tract infections. Can J Infect Dis 1994;5(Suppl C):3-8C.
389. Uzun O, Hayran M, Akova M, et al. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report. J Chemother 1994;6:53-7. (Pubitemid 24115568)
390. Jang TN, Liu CY, Wang FD, et al. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia. Zhonghua Yi Xue Za Zhi (Taipei) 1995;55:302-6.
391. Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995;8:398-402.
392. Oh HM, Ng AW, Lee SK. Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J 1996;37:255-7.
393. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71. (Pubitemid 26347611)
394. Genne D, Siegrist HH, Humair L, et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997;16:783-8. (Pubitemid 27527054)
395. Ho A, Leung R, Lai CK, et al. Hospitalized patients with community-acquired pneumonia in Hong Kong: a randomized study comparing imipenem/cilastatin and ceftazidime. Respiration 1997;64:224-8. (Pubitemid 27179871)
396. Cabellos C, Ariza J, Barreiro B, et al. Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:265-8. (Pubitemid 28356490)
397. Fogarty CM, Sullivan JG, Chattman MS, et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998;7:400-7. (Pubitemid 28513413)
398. Rhew DC, Hackner D, Henderson L, et al. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998;113:142-6.
399. Speich R, Imhof E, Vogt M, et al. Efficacy, safety, and tolerance of piperacillin/ tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:313-7. (Pubitemid 28379316)
400. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine risk class III/IV community-acquired pneumonia patients. Respir Med 2006;100:2129-36. (Pubitemid 44718399)
401. File TM Jr. Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia. Curr Opin Infect Dis 2005;18:123-4.
402. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38(Suppl 1):S16-23.
403. Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003;37:1475-80. (Pubitemid 37494675)
404. Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697-705. (Pubitemid 41759850)
405. Lode H, Grossman C, Choudhri S, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003;97:1134-42. (Pubitemid 37185117)
406. Wallace RJ Jr, Martin RR, Quinones FJ, et al. Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial. Antimicrob Agents Chemother 1981;20:648-52. (Pubitemid 12168043)
407. Grieco MM, Lange M, Daniels JA, et al. Single-blind controlled study of ceftizoxime and cefamandole in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1982;10(Suppl C):223-5. (Pubitemid 13187811)
408. Wallace RJ Jr, Niefield SL, Waters S, et al. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrob Agents Chemother 1982;21:231-5. (Pubitemid 12112795)
409. Keeton GR, Kehoe B, Phillips SW, et al. Ceftazidime and cefamandole in the treatment of pneumonia. J Antimicrob Chemother 1983;12(Suppl A):27-30. (Pubitemid 13000740)
410. Geckler RW, McCormack GD, Goodman JS. Comparison of cefonicid and cefamandole for the treatment of community-acquired infections of the lower respiratory tract. Rev Infect Dis 1984;6(Suppl 4):S847-52.
411. Weber DJ, Calderwood SB, Karchmer AW, et al. Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia. Antimicrob Agents Chemother 1987;31:876-82. (Pubitemid 17084043)
412. Carbon C, Leophonte P, Petitpretz P, et al. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob Agents Chemother 1992;36:833-9.
413. Kissling M. Cefetamet pivoxil in community-acquired pneumonia: an overview. Curr Med Res Opin 1992;12:631-9.
414. Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung 1993;43:1014-7. (Pubitemid 23274365)
415. Aquino R, Lansang MA, Salvador A, et al. The effectiveness and safety of ceftriaxone to cefetamet pivoxil vs ceftazidime to cefetamet pivoxil vs cefoperazone to cefetamet pivoxil in the treatment of community-acquired pneumonia in adult Filipinos. Phil J Intern Med 1994;31:237-40.
416. Liippo K, Tala E, Puolijoki H, et al. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. J Infect 1994;28:131-9. (Pubitemid 24132611)
417. Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/ sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994;13:293-8. (Pubitemid 24139800)
418. De Palma M, Rocchi D, Canepa G, et al. Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. Clin Ther 1995;17:413-24.
419. Hopkins S, Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Curr Ther Res 1995;56:915-25.
420. Aubier M, Lode H, Gialdroni-Grassi G, et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 1996;37(Suppl A):73-82. (Pubitemid 26158807)
421. Hernandez JM, Sides GD, Conforti PM, et al. Clinical efficacy of dirithromycin in patients with bacteremic pneumonia. Clin Ther 1996;18:1128-38. (Pubitemid 27077116)
422. Ortqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 1996;110:1499-506.
423. Portier H, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. J Antimicrob Chemother 1996;37(Suppl A):83-91. (Pubitemid 26158808)
424. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996;37(Suppl A):145-60. (Pubitemid 26158814)
425. Donowitz GR, Brandon ML, Salisbury JP, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther 1997;19:936-53. (Pubitemid 27508929)
426. Drehobl M, Bianchi P, Keyserling CH, et al. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1579-83. (Pubitemid 27289691)
427. Ragnar NS. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother 1997;39:499-508.
428. O'Doherty B, Dutchman DA, Pettit R, et al. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40(Suppl A):73-81. (Pubitemid 28041170)
429. Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. Clin Infect Dis 1998;26:1312-20.
430. Salvarezza CR, Mingrone H, Fachinelli H, et al. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998;41(Suppl B):75-80. (Pubitemid 28152228)
431. Tremolieres F, de Kock F, Pluck N, et al. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:447-53. (Pubitemid 28427370)
432. Zervos M, Nelson M. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia. The Cefepime Study Group. Antimicrob Agents Chemother 1998;42:729-33. (Pubitemid 28216344)
433. Daniel R. Trovafloxacin vs high dose amoxicillin in the treatment of community-acquired bacterial pneumonia. Drugs 1999;58(Suppl 2):304-5. (Pubitemid 29500178)
434. Daniel R. Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia. Drugs 1999;58(Suppl 2):320-2. (Pubitemid 29500184)
435. Grossman RF, Campbell DA, Landis SJ, et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin. J Antimicrob Chemother 1999;43:549-54. (Pubitemid 29182305)
436. Moola S, Hagberg L, Churchyard GA, et al. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 1999;116:974-83. (Pubitemid 29491868)
437. Peterson J. Oral trovafloxacin vs oral cefuroxime ± erythromycin in community acquired pneumonia. Drugs 1999;58(Suppl 2):301-3. (Pubitemid 29500177)
438. Ramirez J, Unowsky J, Talbot GH, et al. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999;21:103-17. (Pubitemid 29106693)
439. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20. (Pubitemid 38842773)
440. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23. (Pubitemid 39177479)
441. Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005;128:2230-7. (Pubitemid 41507564)
442. Blaser MJ, Klaus BD, Jacobson JA, et al. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. Antimicrob Agents Chemother 1983;24:163-7. (Pubitemid 13029318)
443. Cassell GH, Drnec J, Waites KB, et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chemother 1991;27(Suppl A):47-59.
444. Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994;97:28-33.
445. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995;22:219-23.
446. Higuera F, Hidalgo H, Feris J, et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37:555-64. (Pubitemid 26116970)
447. Berman SJ, Sieger B, Geckler W, et al. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. Curr Ther Res 1997;58:903-16. (Pubitemid 28060049)
448. Ailani RK, Agastya G, Mukunda BN, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999;159:266-70. (Pubitemid 29075646)
449. Schonwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection 1999;27:198-202. (Pubitemid 29257745)
450. Sherer Y, Bakshi E, Rotman P, et al. Comparative clinical study of cefonicid, chloramphenicol, and penicillin in community-acquired pneumonia. Int J Mol Med 1998;2:343-8.
451. Stocks JM, Wallace RJ Jr, Griffith DE, et al. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. Am J Med 1989;87(6C):52-6S.
452. Morandini G, Perduca M, Zannini G, et al. Clinical efficacy of azithromycin in lower respiratory tract infections. J Chemother 1993;5:32-6. (Pubitemid 23087493)
453. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998;55:31-45. (Pubitemid 28035123)
454. Moreno S, Garcia-Leoni ME, Cercenado E, et al. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995;20:1195-200.
455. Jackson MA, Burry VF, Olson LC, et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J 1996;15:1049-51. (Pubitemid 26403806)
456. Amsden GW. Pneumococcal macrolide resistance - myth or reality? J Antimicrob Chemother 1999;44:1-6.
457. Perez-Trallero E. Pneumococcal macrolide resistance - not a myth. J Antimicrob Chemother 2000;45:401-3. (Pubitemid 30139255)
458. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999;11:107-18. (Pubitemid 29198092)
459. Moss PJ, Finch RG. The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax 2000;55:83-5. (Pubitemid 30248784)
460. Robenshtok E, Shefet D, Gaafter-Gvili A, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Systemat Rev 2008;(1):CD004418.
461. Shefet D, Robenshtok E, Paul M, et al. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005;165:1992-2000. (Pubitemid 41362622)
462. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456.
463. Sportel JH, Koeter GH, van Altena R, et al. Relation between beta-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease (COPD). Thorax 1995;50:249-53.
464. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4. (Pubitemid 28016230)
465. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44. (Pubitemid 38392978)
466. Simpson JC, Macfarlane JT, Watson J, et al. A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax 2000;55:1040-5.
467. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709-18.
468. Houck PM, Bratzler DW, Nsa W, et al. Antibiotic administration in community-acquired pneumonia. Chest 2004;126:320-1.
469. Metersky ML, Sweeney TA, Getzow MB, et al. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? Chest 2006;130:16-21.
470. Welker JA, Huston M, McCue JD. Antibiotic timing and errors in diagnosing pneumonia. Arch Intern Med 2008;168:351-6. (Pubitemid 351347125)
471. Kanwar M, Brar N, Khatib R, et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-9. (Pubitemid 46981647)
472. Schulin T, Wennersten CB, Ferraro MJ, et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998;42:1520-3. (Pubitemid 28257665)
473. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72.
474. Burgess DS, Lewis JS 2nd. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000;22:872-8. (Pubitemid 30625919)
475. MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 1997;24:457-67. (Pubitemid 27096804)
476. Mandell LA, Bergeron MG, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Can J Infect Dis 1995;6:306-15. (Pubitemid 26027973)
477. Siegel RE, Alicea M, Lee A, et al. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 1999;6:217-22. (Pubitemid 29342881)
478. Nathwani D. Sequential switch therapy for lower respiratory tract infections: a European perspective. Chest 1998;113(3 Suppl):211-8S.
479. el Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355.
480. Pedro-Botet L, Yu VL. Legionella: macrolides or quinolones? Clin Microbiol Infect 2006;12(Suppl 3):25-30.
481. Sabria M, Pedro-Botet ML, Gomez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005;128:1401-5. (Pubitemid 41324424)
482. Blazquez Garrido RM, Espinosa Parra FJ, Alemany Frances L, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005;40:800-6.
483. Mykietiuk A, Carratala J, Fernandez-Sabe N, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005;40:794-9. (Pubitemid 40365496)
484. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: points of interest. Clin Infect Dis 2006;43:1603-11. (Pubitemid 44910994)
485. Grau S, Antonio JM, Ribes E, et al. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia. Int J Antimicrob Agents 2006;28:249-52. (Pubitemid 44223978)
486. Hubbard RB, Mathur RM, MacFarlane JT. Severe community-acquired legionella pneumonia: treatment, complications and outcome. Q J Med 1993;86:327-32. (Pubitemid 23160833)
487. Kirby J, Polis G, Romansky MJ. A controlled blind study of pneumococcal pneumonia treated with tetracycline and tetracycline plus 6-methyl prednisolone. Antibiot Ann 1959;7:175-81.
488. Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-8. (Pubitemid 38314445)
489. Genne D, Sommer R, Kaiser L, et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006;25:159-66.
490. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5. (Pubitemid 39490781)
491. Heffner JE, McDonald J, Barbieri C, et al. Management of parapneumonic effusions. An analysis of physician practice patterns. Arch Surg 1995;130:433-8.
492. Light RW. A new classification of parapneumonic effusions and empyema. Chest 1995;108:299-301.
493. Heffner JE, Brown LK, Barbieri C, et al. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med 1995;151:1700-8.
494. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med 2006;119:877-83. (Pubitemid 44415617)
495. Finley C, Clifton J, Fitzgerald JM, et al. Empyema: an increasing concern in Canada. Can Respir J 2008;15:85-9. (Pubitemid 351676396)
496. Farjah F, Symons RG, Krishnadasan B, et al. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg 2007;133:346-51.
497. Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax 2003;58(Suppl 2):ii18-28.
498. Almirall J, Bolibar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008;31:1274-84.
499. Baik I, Curhan GC, Rimm EB, et al. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med 2000;160:3082-8.
500. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000;342:681-9. (Pubitemid 30131420)
501. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000;55:987-99.
502. Berntsson E, Blomberg J, Lagergard T, et al. Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol 1985;4:268-72. (Pubitemid 15072446)